Dr. Carolina Garcia Rizo is a veteran C-suite executive with a track record of high-value AI biopharma exits. As Chief Business Officer, she led the acquisition of Just Biotherapeutics (pioneering AI in biologics development and manufacturing) and played a pivotal role in the IPO of Immuneering (NASDAQ: IMRX). Her leadership experience also includes serving as a Partner at Evexia Biofund, leading oncology/genomics BD at Roche, strategic turnarounds at Cepheid (Danaher), and innovation strategy at Monitor-Deloitte.
Today, she serves as an independent board member at QuantPi, a leader in trustworthy AI supporting NVIDIA and HPE. An active investor and advisor across the AI-Bio ecosystem, she lends her strategic expertise to pioneering biotechs including Oisin Biotechnologies.
A recognized visionary, Dr. Rizo authored the 2018 chapter “The Digital and In Silico Therapeutics Revolution” (Digital Health, Springer), accurately forecasting the computational shift in medicine years before the current market inflection. Recognized as a “Remarkable Woman in AI 2025,” she holds an MBA from MIT, a PhD in Atomic Physics, and was a Fulbright Fellow at UC Berkeley. With a foundation in in silico proteomics research at the Max Planck Institute and UCSF, she uniquely blends deep science with high-stakes business execution.
